Month: January 2013

Press Release


Denosumab is a RANK ligand (RANKL) inhibitor indicated for:  Treatment of postmenopausal women with osteoporosis at high risk for fracture Mechanism of action: Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.  Denosumab prevents RANKL from activating its receptor, RANK, […]

Read More